• Metadoro
  • Productos
  • Noticias y análisis

Noticias y análisis

Consulte las perspectivas de mercado compartidas por los miembros de nuestra comunidad
26.01.2023
Top 5 perdedores de 2022: Consumo discrecional

En 2022, todo el sector de consumo discrecional, que incluye empresas que producen bienes no esenciales: automóviles, ropa, artículos de lujo, hoteles, restaurantes, etc., fue muy afectado. Cuando llegan tiempos difíciles, la gente sigue comprando comida, pero comienza a ahorrar en otras áreas. Los temores sobre la inflación y la recesión inminente provocaron el colapso del ETF XLY en casi 40% a finales de año. Sin embargo, tales reducciones a menudo brindan excelentes oportunidades de inversión, ya que es raro ver acciones de compañías icónicas como Nike, Toyota y Home Depot tan lejos de sus valores máximos. Los informes macroeconómicos recientes apuntan a que quizás los temores de una disminución en la demanda de los consumidores son demasiado pesimistas. Las ventas minoristas en EE.UU. durante la temporada navideña fueron bastante fuertes (según Mastercard, el gasto en los Estados Unidos aumentó 7.6% interanual entre el 1 de noviembre y el 24 de diciembre), y los empleadores siguen buscando nuevo personal. Tal dinámica favorece el aumento de los salarios y la preservación de la actividad de consumo.

28.03.2023
Axie Infinity: el pionero de play-2-earn ha perdido relevancia

En 2021, el juego Axie Infinity basado en blockchain se convirtió en un verdadero descubrimiento: la cantidad de personas que querían ganar dinero criando animales y participando en batallas se disparó, gracias a lo cual el valor del token se disparó en más del 1000% en noviembre. Desde entonces, muchos proyectos han intentado repetir el éxito de Axie, pero todos han tenido el mismo final triste.

El problema de proyectos de este tipo es fundamental. Cuando un token de juego comienza a cotizar en una bolsa, su precio se vuelve extremadamente vulnerable a la afluencia de usuarios. Tan pronto como disminuye, se vuelve imposible mantener la presión de los vendedores, como resultado de lo cual las cotizaciones caigan como una piedra. Cabe recordar que con el aumento del valor de las monedas, aumenta el umbral de entrada. No todos pueden pasar mucho tiempo en un juego muy monótono, especialmente cuando la recompensa financiera se vuelve mínima. Axie también sufre de este malestar. Diversas estrategias de marketing, como mayores recompensas para los jugadores activos, no son capaces de cambiar fundamentalmente la situación. Si a finales de 2021 el número de compradores únicos de AXS era alrededor de 500 mil, en los últimos meses su número no ha superado los 20 mil. En este sentido, a los inversores se recomienda buscar nuevos proyectos que puedan dispararse durante el próximo ciclo alcista. Son los primeros usuarios los que tienen la oportunidad de ganar mucho dinero, incluso vendiendo sus tokens a especuladores lentos que realizan compras después de que sube el precio.

16.03.2023
¿Qué hará el S&P 500 después de caer a los 3400 puntos?

Los futuros sobre el índice de mercado amplio S&P 500 están resbalando cada vez más, mostrando que el intento de romper el límite superior del canal descendente a principios de febrero, aparentemente, no tuvo éxito. Y si es así, entonces es hora de considerar un plan aproximado para la caída del principal índice de referencia bursátil. En la mayoría de los casos, luego de que un instrumento financiero no logra romper un nivel importante, recibe un fuerte contraataque debido a la debilidad mostrada. Creo que en el caso de los futuros del S&P 500, esto significa un retorno lógico a la mitad del actual canal bajista en la zona de los 3400 puntos. Donde, como podemos ver, se ubica el primer nivel técnico muy fuerte. Tal caída en el índice de referencia bursátil estadounidense se correlaciona bien con la situación actual, cuando los mercados están temblando debido a la crisis bancaria en EE. UU. y Europa. Personalmente, prácticamente no tengo dudas sobre una caída a este nivel. Pero luego, las opciones demasiado polares y extremas sugieren una bifurcación en 3400 puntos.

Es posible que la situación se aclare durante la caída del mercado, pero hasta ahora lo máximo con lo que se puede contar vendiendo futuros del índice S&P 500, es su caída en el próximo mes y medio entre 12 y 14%.

21.04.2022
Tres acciones que están atrayendo la atención de los alcistas: Procter & Gamble

El informe financiero del famoso fabricante mundial de productos del segmento de consumo del primer trimestre de 2022 mostró todos los signos de un crecimiento estable de los ingresos, que alcanzaron los 19,38 mil millones de dólares, un 3,5% más de lo que esperaban los analistas de Wall Street, y también un 7% más del período correspondiente en 2021. Pero en comparación con la temporada prenavideña de fin de año, las cifras son, por supuesto, menores. Contrariamente a las afirmaciones de que las presiones de los precios de compra están perjudicando las ganancias de los productores, las ganancias por acción (EPS) aumentaron 7 centavos durante año a 1,33 dólares. Los suministros de productos médicos como Oral-B y Pepto-Bismol aumentaron un 13%.

Procter & Gamble elevó su pronóstico de ventas anual y confirmó que la demanda de productos de higiene y cuidado de la salud sigue siendo estable a pesar del aumento de los precios. "Orgánicamente, el crecimiento de los ingresos será del 6% al 7%", dijo la compañía, que está por encima del pronóstico de consenso de los analistas del 5,5%. Las acciones de Procter & Gamble subieron un 3% inmediatamente después de los datos trimestrales, deteniéndose en 88 centavos por debajo de su máximo de enero. Está claro que el precio no se mantendrá en los niveles actuales después de subir un 17,5% desde enero de 2021. Andre Schulten, vicepresidente de asuntos financieros de la compañía, dijo que espera una disminución de BPA de 1 centavo en el tercer trimestre debido al conflicto militar en Ucrania. En el cuarto trimestre, esta cifra puede disminuir en otros 4 centavos. El comentario sigue a la decisión de la compañía de dejar de invertir en Rusia y "reducir sustancialmente" su línea de productos, centrándose en productos de higiene, productos médicos y de cuidado personal. Rusia y Ucrania representan alrededor del 1,5% de todas las ventas de la empresa.

El negocio basado en la producción de productos de consumo diario suele ser más resistente durante una tormenta inflacionaria. Produce productos simples y necesarios que las personas han estado usando durante años y están acostumbrados a ellos. Es poco probable que las amas de casa renuncien a Pampers, Tampax o Always, y es poco probable que sus esposos que usan maquinillas para afeitar Gillette, estén listos para cambiar a otras marcas, especialmente cuando sus precios también están aumentando.

19.01.2023
Top 5 líderes de crecimiento en 2022: la soja

En el verano de 2022, los futuros de soja alcanzaron su punto máximo, con un aumento de precio del 35% desde principios de año. Al analizar este instrumento, se debe tener en cuenta que la soja se usa en dos direcciones a la vez: no solo es una parte importante de la industria alimentaria (incluso se usa para alimentar el ganado), sino que también se utiliza para producir biodiesel para automóviles. En ese sentido, es muy similar al maíz, cuyos futuros también están en el mercado. Los principales impulsores de los aumentos de precios son la alta inflación, que eleva el costo de producción, la falta de fertilizantes y la incertidumbre relacionada con el clima en las regiones clave donde se cultiva la soja. En 2022, se cosecharon 163 millones de toneladas de soja en América Latina (principalmente en Brasil y Argentina), más que en los Estados Unidos, China e India. Varios brokers agrícolas esperan un nuevo aumento en la inflación de los alimentos. Se necesitan cosechas récord para satisfacer la demanda actual, mientras que un mal clima y los altos precios de la energía limitan significativamente la oferta.

B
McDonald's Fast Recovery on Smaller Damage

McDonald's seemingly gets away with its late October's E. coli incident. One person dead and dozens sick from infection linked to Quarter Pounder popular hamburgers. The market value of this huge and most famous fast food chain lost up to 12% after facing a following drop in visitors over the next couple of months. The deepest point of a pullback was at nearly $276.5 on January 16. However, it didn't take long to see the price jumping above $310. Thus, shares of McDonald's closed at $308.42 this Monday's regular session after a 4.8% bullish jump to follow the firm's comparable sales during the last quarter that topped consensus bets. The average estimate of Bloomberg analyst pool was focused around a possible quarterly decline around 0.90%. Global comparable sales of McDonald's expanded by 0.4% in the last three months of 2024, with performance being led reportedly by the Middle East and Japan. Demand pressure was limited after easing due to an informal boycott of Western chains over their pro-Israeli stance in the Gaza conflict. It is probably a thing of the past. And now weakness in the largest market for McDonald's, which is certainly the U.S., has been mostly overcome as well, due to lower-priced options and "exciting menu innovations" like a Chicken Big Mac and bringing back snack wraps to restore consumer confidence, according to the fast-food chain's CEO Chris Kempczinski. Extending its $5 meal deal into December helped much, but the average transaction size reached more than $10 in the U.S. Group-wide, MCD revenue was only 0.3% lower YoY at $6.39 billion, while operating income rose 2.4% to $2.87 billion, despite the shocks, including an additional pre-tax expense of $221 million because of a restructuring process.

I mentioned my target price at $325 to be touched even before the end of winter or at least in the beginning of spring, citing factors of more cost-conscious consumers to choose reasonably priced food, attractive and new limited-time offerings and potentially lower interest rates. The last argument remains an unfulfilled hope, but the stock has travelled most of its supposed path without a proper contribution from central banks. This means the ultimate goal could be shifted even to a higher price area, let's say between $330 and $350. By the way, Citigroup analysts see a Buy rating with a $336 price target. In early November, we discussed a great chance of adding more buy positions for MCD in case of retesting "the levels around $275 or a bit lower" as I didn't believe in larger damage to the stock. This assumption was one hundred percent hitting in terms of the bottoming area. The next question is how accurately the upper target will be achieved. Hope to see it soon.

When pointing at potential post-election gainers, I added a few more U.S. budget chain store names like Target (TGT) and Walmart (WMT), besides McDonald's. If Target shares have so far only seen a partial recovery, then Walmart's price has found a path from $82.5 three months ago to $103 in the first week of February. Gradually, the turn of the remaining forecasts comes.

2877
Tariff Wars Are Buying Opportunities

Major world market indices tend to ignore the impact of U.S. president Donald Trump's trade war actions. The investment community calmly digested his announcement of 25% tariffs on all steel and aluminium imports to the U.S., just a few days after unsurprising 10% on China's goods. The metal tariffs will be added to current levies, which Trump already imposed during his first term, as the measures were partially retained by the Biden administration. As a result, the S&P 500 broad barometer of Wall Street stopped climbing around 6,100 for going backwards last Friday's evening on February 7 and began regular trading on February 10 just one step below the psychologically important figure of 6,000, particularly at 5,992.80. However, it ended the regular session at 6,065.50, which represented a gain of more than a full percentage point. These same types of smoothed-out effects were seen during Trump's first term. Mutual protectionist measures clearly limited global economic growth in 2017-2019, but did not prevent the stock market rally from developing further to new record highs. At that time, the U.S. S&P 500 has grown from nearly 2,250 to almost 3,400 points. In 2025, the capital flight from accumulated inflation seems to be equal to a scorched earth effect under the feet of rich and middle class who previously held conservatively to cash deposits and Treasury notes, and now enhancing their stakes in sustainable businesses and pushing risk-on buttons for the artificial intelligence as well as various big data and cloud tech names.

Investors may be hoping that Trump's tough first steps are more of a bid to open subsequent trade talks with more balanced end-terms. Just new positioning for the new division of our small world. If so, then some relief may be offered at least to Mexico and Canada as immediate neighbours. As an example, Trump already postponed actually imposing 25% tariffs on these two major suppliers for the U.S. industries. Trump's team also granted quotas for exemptions from initial tariffs during his first term, for particular countries, and then struck a "big deal" with China based on concessions from hard-line starting positions. We consider the idea of markets expecting similar scenarios here and now.

It seems, however, that the degradation of the purchasing value of depreciated dollars and euros, as a result of the intense previous activity of the printing press in the COVID times, as well as printing money because of geopolitical tensions and internal problems, is simply a much stronger driver of buying more stocks despite climbing indexes compared to the negative factor of tariff battles. January inflation may push the S&P 500 even more upstairs if signs of cooling price growth will be demonstrated on a MoM or YoY basis. But even sticky inflation pressure scenarios would result in some delay in the bullish race, though reversal patterns on charts could currently be excluded from being considered.

Even though the leading EU economies are clearly unhappy with the prospect of Trump's nearly promised tariffs for the EU as well, European stock markets continue to grow as if nothing had happened. Although German industrial companies are suffering from expensive energy supplies, the German DAX 40 index of blue chips (GER40) is at new historical highs and only a hundred points away from the 22,000 mark. It was ranging from 19,000 to 19,650 before the end of last autumn, but managed to gain double-digit percentages in a couple of months. This looks as a proof that market growth is not at all identical to economic growth forecasts. A need to avoid risks is a more notable motivator than economic comparison or the AI-driven optimism led by Nvidia. Yet, the recent sell-off in Nvidia, triggered by Chinese startup DeepSeek’s breakthrough, is a buying opportunity again, which is confirmed by a nearly 17% rebound from fresh dips.

3170
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Graph Is Likely to Recover Strongly

The Graph (GRT) is up 8.0% this week to $0.1365, outperforming the broader crypto market, where Bitcoin (BTC) is rising by 2.7% to $97,820. The altcoin is now trading slightly above the level where the Trump-driven rally began last November. After gaining 159%, GRT has since lost most of those gains, bottoming out at $0.1026 on February 3.

GRT's price movements are largely influenced by the overall crypto market trend. If BTC manages to stay above $90,000 by the end of February, GRT could see a strong recovery from the $0.1000–$0.1500 levels.

3679
Winning on Weight Losers

Eli Lilly (LLY) got another boost to grow stronger. A high-speed racing biopharma monster just confirmed the globally rising need in its weight-loss drugs at the practical level. What we can ascertain is that the price bottoming stage is finally complete after an overlong correction from early September 2024 to mid-January 2025. As we pointed to a chance for Eli Lilly's brief visits to the major technical support area between $700 and $750, before inevitable recovery to the levels above $950, that's how it perfectly goes. A cowardly attempt to retest its November 18 intraday low at $711.40 per share was limited to touching $725 after two months on January 17. Now the price is soaring to nearly $888 on solid quarterly numbers issued in the first week of February. Zepbound treatment to make it easier to fight obesity cases is another brand name for tirzepatide, which was initially developed as Mounjaro for diabetes. This dual action injection drug, approved by the U.S. FDA in May 2022 for type 2 diabetes and then in November 2023 to reduce excess body weight and maintain weight reduction long term. Backed by a celebrity effect from Hollywood stars, this kind of medicare gradually became crazy popular among hundreds of millions of patients. Temporary signs of weakness in sales of the drugs last autumn were rather related to logistical bottlenecks. For this reason, sales of Mounjaro were $3.11 billion, and Zepbound sales amounted to $1.26 billion in Q3, even though analyst polls predicted $4.20 billion for Mounjaro and $1.69 billion for Zepbound. It was too optimistic scenario, and failure to meet it disappointed market bulls, following the stock's doubling in value in the previous two years. This problem appears to be fixed after the most valuable healthcare company in the world reported Q4 sales for its Zepbound and Mounjaro of $1.91 billion and $3.53 billion, respectively. The total increase was almost 25% over the course of one quarterly period. The company's current estimate is that U.S. growth of its diabetes and weight-loss drugs to be consistent with 2024, which apparently satisfied the investing crowd.

Lilly also projected its annual profit well above Wall Street estimates, as it is planning to grab between $22.50 and $24.00 per share in 2025, compared to average bets on $22.86 per share, according to LSEG data, with the midpoint of the announced range being 32% up from the last year. This means it is back on track hopefully after a harsh period with restoring order in supply chains. In addition, Lilly CEOs noted they are building manufacturing capacity for its new experimental oral obesity drug Orforglipron to ease some worries over its advance cycle. Eli Lilly is launching its Mounjaro in new markets like China, India, Brazil and Mexico, for both diabetes and obesity. Analyst polls expect revenues of above $59 billion for 2025. Lilly's rival Novo Nordisk, a Danish producer of Wegovy drug, forecasted slower growth vs its results in 2024. JAMA Internal Medicine reported that patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose 15% or more of their weight, compared with patients taking the second-place drug by Novo Nordisk.

The entire market for weight-loss treatments is widely estimated at more than $150 billion by the early 2030s. To put it in perspective, Eli Lilly is three times larger in terms of market value than Merck and five times more expensive than Pfizer, the other two giants of the pharmaceutical industry. Eli Lilly's achievements include the U.S. regulatory approval of Kisunla, the brand name of Donanemab, which is a treatment of Alzheimer's disease, and of Jaypirca in Japan to treat lymphoma.

3365
85

Únete a nuestra comunidad

Comparta sus observaciones profesionales y aficionadas, intercambie experiencias, anticipe desarrollos

Categoría
Todo
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instrumentos
Autor
Todo
Metadoro
Colaboradores